One that you have to take into consideration is the way their staff works
In the landmark STEP 1 trial (Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding and colleagues, New England Journal of Medicine , 2021), 1,961 adults who took weekly semaglutide (2.4 mg) plus lifestyle support lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, and 86% achieved at least 5% weight loss
d) condensing Boc-His(X)-Aib-Glu(OtBu)-Gly-OH (fragment-1) with peptide obtained in step-c) in presence of a coupling agent in in-situ manner followed by deprotection in presence of base to obtain protected Semaglutide
This highlights the potential of targeting gut-brain interactions to improve motivational symptoms, such as loss of appetite or anhedonia
For microdosing protocols, fresh preparation is generally preferred over prefilling